<DOC>
	<DOCNO>NCT00476268</DOCNO>
	<brief_summary>Efficacy tolerability fix combination beclometasone/formoterol patient moderate severe persistent asthma .</brief_summary>
	<brief_title>Efficacy Tolerability Beclometasone/Formoterol Single Inhaler Patients With Moderate Severe Persistent Asthma</brief_title>
	<detailed_description>The purpose study evaluate efficacy tolerability beclometasone/formoterol single inhaler twice daily regimen patient moderate severe persistent asthma . Patients randomise receive either beclometasone/formoterol single inhaler ( total daily dose : BDP/FF 400/24 mcg ) beclometasone CFC + formoterol DPI ( total daily dose : BDP 1000 mcg + FF 24 mcg ) beclometasone CFC ( total daily dose : BDP 1000 mcg ) 24 week treatment .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Clinical diagnosis moderate severe persistent asthma ( accord GINA 2002 guideline ) FEV1 &gt; 40 % &lt; 80 % predict normal postbronchodilator ( least 0.7 L absolute value ) Patients already treat least 2 month association inhale corticosteroid plus LABA dos : 750 1000 µg beclomethasone dipropionate equivalent ( ICSs ) 24 µg formoterol 100 µg salmeterol ( LABAs ) Or patient naïve LABA already treat least 2 month inhale corticosteroid ( dos ) associate daily use SABA and/or clinical symptom &gt; 3 time week prior inclusion A document positive response reversibility test . Pregnant lactate female woman childbearing potential without efficient contraception . Heavy smoker define smoke &gt; 10 pack year . Evidence asthma exacerbation cause hospitalisation require treatment oral/parenteral corticosteroid evidence symptomatic airway infection 4 week prior inclusion ( 3 month slowrelease corticosteroid ) . Seasonal asthma asthma occur episodic exposure allergen occupational chemical sensitizer . Clinically significant unstable concomitant disease , include clinically significant laboratory abnormality . Patients abnormal QTc interval value ECG test , define &gt; 450 msec male &gt; 470 msec female . Evidence asthma worsen week precede randomisation ( e.g . PEF variability &gt; 30 % 2 consecutive day , SABA use &gt; 8 puffs/day 2 consecutive day , nocturnal awakening due asthma symptom 3 consecutive day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>